VIENNA — Nipocalimab, iscalimab, and tibulizumab, but not lusvertikimab, appear to be promising new agents for Sjögren disease that warrant further investigation, suggest the results of four separate ...
Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren’s syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A ...
Sjogren’s syndrome (SS) is a chronic autoimmune disorder where the body attacks the moisture-producing glands and can overlap with other autoimmune diseases, most commonly lupus and rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results